{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:25:39Z","timestamp":1759411539794,"version":"3.41.2"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T00:00:00Z","timestamp":1630022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007949","name":"Reumatikerf\u00f6rbundet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016670","name":"Region \u00d6sterg\u00f6tland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007857","name":"Stiftelsen Konung Gustaf V:s 80-\u00e5rsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006129","name":"Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic on individuals with arthritis has been highlighted whereas data on other rheumatic diseases, e.g., systemic lupus erythematosus (SLE), are scarce. Similarly to SLE, severe SARS-CoV-2 infection includes risks for thromboembolism, an unbalanced type I interferon response, and complement activation. Herein, SARS-CoV-2 antibodies in longitudinal samples collected prior to vaccination were analyzed and compared with SLE progression and antinuclear antibody (ANA) levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>One hundred patients (83 women) with established SLE and a regular visit to the rheumatologist (March 2020 to January 2021) were included. All subjects donated blood and had done likewise prior to the pandemic. SARS-CoV-2 antibody isotypes (IgG, IgA, IgM) to the cell receptor-binding S1-spike outer envelope protein were detected by ELISA, and their neutralizing capacity was investigated. IgG-ANA were measured by multiplex technology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>During the pandemic, 4% had PCR-confirmed infection but 36% showed SARS-CoV-2 antibodies of \u22651 isotype; IgA was the most common (30%), followed by IgM (9%) and IgG (8%). The antibodies had low neutralizing capacity and were detected also in prepandemic samples. Plasma albumin (<jats:italic>p<\/jats:italic>= 0.04) and anti-dsDNA (<jats:italic>p<\/jats:italic>= 0.003) levels were lower in patients with SARS-CoV-2 antibodies. Blood group, BMI, smoking habits, complement proteins, daily glucocorticoid dose, use of hydroxychloroquine, or self-reported coronavirus disease 2019 (COVID-19) symptoms (except fever, &amp;gt;38.5\u00b0C) did not associate with SARS-CoV-2 antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our data from early 2021 indicate that a large proportion of Swedish SLE patients had serological signs of exposure to SARS-CoV-2 but apparently with a minor impact on the SLE course. Use of steroids and hydroxychloroquine showed no distinct effects, and self-reported COVID-19-related symptoms correlated poorly with all antibody isotypes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.724047","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T15:57:41Z","timestamp":1630943861000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic"],"prefix":"10.3389","volume":"12","author":[{"given":"Johanna","family":"Sj\u00f6wall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Azharuddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Frodlund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Sandner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Dahle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorma","family":"Hinkula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Sj\u00f6wall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,27]]},"reference":[{"key":"B1","first-page":"annrheumdis","article-title":"Prevalence and Clinical Outcomes of COVID-19 in Patients With Autoimmune Diseases: A Systematic Review and Meta-Analysis","volume-title":"Ann Rheum Dis","author":"Akiyama","year":"2020"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1136\/annrheumdis-2020-217787","article-title":"Are Patients With Systemic Lupus Erythematosus at Increased Risk for COVID-19","volume":"80","author":"Favalli","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-219845","article-title":"Impact of the COVID-19 Pandemic on Morbidity and Mortality in Patients With Inflammatory Joint Diseases and in the General Population: A Nationwide Swedish Cohort Study","volume":"80","author":"Bower","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic Lupus Erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2018-000270","article-title":"Interferon Pathway in SLE: One Key to Unlocking the Mystery of the Disease","volume":"6","author":"Ronnblom","year":"2019","journal-title":"Lupus Sci Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1038\/cti.2016.26","article-title":"Targeted Therapeutics in SLE: Emerging Strategies to Modulate the Interferon Pathway","volume":"5","author":"Oon","year":"2016","journal-title":"Clin Transl Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-021-00608-z","article-title":"Systemic and Organ-Specific Immune-Related Manifestations of COVID-19","volume":"17","author":"Ramos-Casals","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6027","article-title":"Impaired Type I Interferon Activity and Inflammatory Responses in Severe COVID-19 Patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01310-z","article-title":"Actionable Druggable Genome-Wide Mendelian Randomization Identifies Repurposing Opportunities for COVID-19","volume":"27","author":"Gaziano","year":"2021","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.06.012","article-title":"COVID-19 in Systemic Lupus Erythematosus: Data From a Survey on 417 Patients","volume":"50","author":"Ramirez","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(20)30161-2","article-title":"COVID-19 and Systemic Lupus Erythematosus: A Case Series","volume":"2","author":"Gartshteyn","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001531","article-title":"A Case of Systemic Lupus Erythematosus Flare Triggered by Severe Coronavirus Disease 2019","volume":"26","author":"Raghavan","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"B13","article-title":"Systemic Lupus Erythematosus and Infection: A Controlled and Prospective Study Including an Epidemiological Group","volume":"55","author":"Nived","year":"1985","journal-title":"Q J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60954-X","article-title":"Immunopathogenic Mechanisms of Systemic Autoimmune Disease","volume":"382","author":"Wahren-Herlenius","year":"2013","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd3876","article-title":"Prothrombotic Autoantibodies in Serum From Patients Hospitalized With COVID-19","volume":"12","author":"Zuo","year":"2020","journal-title":"Sci Transl Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05359-y","article-title":"High Levels of Anti-SSA\/Ro Antibodies in COVID-19 Patients With Severe Respiratory Failure: A Case-Based Review: High Levels of Anti-SSA\/Ro Antibodies in COVID-19","volume":"39","author":"Fujii","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0320-7","article-title":"Complement as a Target in COVID-19","volume":"20","author":"Risitano","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0165373","article-title":"Autoantibodies Against Modified Histone Peptides in SLE Patients Are Associated With Disease Activity and Lupus Nephritis","volume":"11","author":"Dieker","year":"2016","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1177\/1358863X21995566","article-title":"Venous Thromboembolism in COVID-19: A Systematic Review and Meta-Analysis","volume":"26","author":"Kollias","year":"2021","journal-title":"Vasc Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26028","article-title":"Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis","volume":"89","author":"Sormani","year":"2021","journal-title":"Ann Neurol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13075-015-0521-9","article-title":"Application of the 2012 Systemic Lupus International Collaborating Clinics Classification Criteria to Patients in a Regional Swedish Systemic Lupus Erythematosus Register","volume":"17","author":"Ighe","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.berh.2005.03.010","article-title":"Assessment of Patients With Systemic Lupus Erythematosus and the Use of Lupus Disease Activity Indices","volume":"19","author":"Griffiths","year":"2005","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390303","article-title":"The Development and Initial Validation of the Systemic Lupus International Collaborating Clinics\/American College of Rheumatology Damage Index for Systemic Lupus Erythematosus","volume":"39","author":"Gladman","year":"1996","journal-title":"Arthritis Rheum"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling Valuations for EuroQol Health States","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.102340","article-title":"Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels Predict Damage Accrual in Patients With Recent-Onset Systemic Lupus Erythematosus","volume":"106","author":"Enocsson","year":"2020","journal-title":"J Autoimmun"},{"volume-title":"Alinity M SARS-CoV-2 AMP Kit (EUA). Instructions for Use: Package Insert. Abbott Molecular","year":"2019","key":"B26"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6284","article-title":"DNA Vaccine Protection Against SARS-CoV-2 in Rhesus Macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6952","article-title":"A Neutralizing Human Antibody Binds to the N-Terminal Domain of the Spike Protein of SARS-CoV-2","volume":"369","author":"Chi","year":"2020","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2020.104468","article-title":"Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for Detection of IgA and IgG Antibodies","volume":"129","author":"Beavis","year":"2020","journal-title":"J Clin Virol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.11.2000266","article-title":"Serological and Molecular Findings During SARS-CoV-2 Infection: The First Case Study in Finland, January to February 2020","volume":"25","author":"Haveri","year":"2020","journal-title":"Euro Surveill"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00802-20","article-title":"Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding","volume":"5","author":"Byrnes","year":"2020","journal-title":"mSphere"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.6.5.725-728.1999","article-title":"A New Method With General Diagnostic Utility for the Calculation of Immunoglobulin G Avidity","volume":"6","author":"Korhonen","year":"1999","journal-title":"Clin Diagn Lab Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.610688","article-title":"Humoral Responses and Serological Assays in SARS-CoV-2 Infections","volume":"11","author":"Galipeau","year":"2020","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":":e001594","DOI":"10.1136\/rmdopen-2021-001594","article-title":"Point of View on the Vaccination Against COVID-19 in Patients With Autoimmune Inflammatory Rheumatic Diseases","volume":"7","author":"Furer","year":"2021","journal-title":"RMD Open"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00114-4","article-title":"Evaluation of SARS-CoV-2 IgG Antibody Reactivity in Patients With Systemic Lupus Erythematosus: Analysis of a Multi-Racial and Multi-Ethnic Cohort","volume":"3","author":"Saxena","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.10.003","article-title":"A Volcanic Explosion of Autoantibodies in Systemic Lupus Erythematosus: A Diversity of 180 Different Antibodies Found in SLE Patients","volume":"14","author":"Yaniv","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B37","doi-asserted-by":"publisher","first-page":":1163","DOI":"10.3390\/diagnostics11071163","article-title":"COVID-19 Antibody Detecting Rapid Diagnostic Tests Show High Cross-Reactivity When Challenged With Pre-Pandemic Malaria, Schistosomiasis and Dengue Samples","volume":"11","author":"Vanroye","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1101\/2020.08.07.20169961","article-title":"Neutralizing Antibody Response in Non-Hospitalized SARS-CoV-2 Patients","volume-title":"medRxiv","author":"Ruetalo","year":"2020"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals","volume":"584","author":"Robbiani","year":"2020","journal-title":"Nature"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and Immunological Assessment of Asymptomatic SARS-CoV-2 Infections","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1038\/s41467-021-23074-3","article-title":"Cross-Reactive Serum and Memory B-Cell Responses to Spike Protein in SARS-CoV-2 and Endemic Coronavirus Infection","volume":"12","author":"Song","year":"2021","journal-title":"Nat Commun"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.10.104","article-title":"High Prevalence of Pre-Existing Serological Cross-Reactivity Against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in Sub-Saharan Africa","volume":"102","author":"Tso","year":"2021","journal-title":"Int J Infect Dis"},{"key":"B43","doi-asserted-by":"crossref","DOI":"10.1111\/vox.13076","article-title":"ABO Blood Group and COVID-19: A Review on Behalf of the ISBT COVID-19 Working Group","volume-title":"Vox Sang","author":"Goel","year":"2021"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/pcmedi\/pbaa036","article-title":"Significant Reduction of Humoral Response to SARS-CoV-2 4 Months After the Diagnosis of COVID-19","volume":"4","author":"Zhang K","year":"2021","journal-title":"Precis Clin Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2025179","article-title":"Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons With Mild Covid-19","volume":"383","author":"Ibarrondo","year":"2020","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/apm.13112","article-title":"The Swedish Public Health Response to COVID-19","volume":"129","author":"Tegnell","year":"2021","journal-title":"APMIS"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.666114","article-title":"False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases","volume":"12","author":"Kharlamova","year":"2021","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.11.013","article-title":"Solid-Phase Classical Complement Activation by C-Reactive Protein (CRP) is Inhibited by Fluid-Phase CRP-C1q Interaction","volume":"352","author":"Sjowall","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2006.03313.x","article-title":"Cytokine Induction by Circulating Immune Complexes and Signs of in-Vivo Complement Activation in Systemic Lupus Erythematosus are Associated With the Occurrence of Anti-Sjogren\u2019s Syndrome A Antibodies","volume":"147","author":"Mathsson","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100007","article-title":"Prolonged Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Frequency and Outcome","volume":"37","author":"Steiman","year":"2010","journal-title":"J Rheumatol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa382","article-title":"Long-Term Outcomes in Systemic Lupus Erythematosus: Trends Over Time and Major Contributors","volume":"59","author":"Arnaud","year":"2020","journal-title":"Rheumatology (Oxford)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.724047\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T17:59:49Z","timestamp":1673200789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.724047\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,27]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2021.724047"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.724047","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2021,8,27]]},"article-number":"724047"}}